A recent meta-analysis demonstrated that GLP-1 receptor agonists reduce atherosclerotic cardiovascular events [41–43], while thiazolidinediones are associated with stroke reduction but increased heart failure risk [44,45], and sulfonylureas are linked to increased cardiovascular risk and mortality [46,47]. This evidence concerns the gene GLP1R and stroke disorder.